Organic Chemical – Page 40

Novartis Enhances Mid-Term Growth Projections Following Strategic Transformation

1 year ago talkbio0Tagged Drug Industry, growth projections, Mid-Term, Novartis, pipeline

Novartis, mid-term guidance, growth projections, pharmaceutical industry, innovative medicines, pipeline development

Novartis CEO Reveals Strategic Pipeline Reduction by 40% Based on Data-Driven Insights

1 year ago talkbio0Tagged clinical pipeline, Data-Driven, Decision, Drug Industry, Novartis, strategic reduction

Novartis, clinical pipeline, data-driven decisions, pharmaceutical industry, strategic reduction

NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations

1 year ago talkbio0Tagged CETP, cholesterol-lowering drugs, Expectations, inhibitors, investor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 trials

NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction

GSK Advances Regulatory Filings for Linerixibat Following Successful Phase 3 Trial in PBC Itch Treatment

1 year ago talkbio0Tagged Cholestatic pruritus, Linerixibat, Phase 3 trial, Primary Biliary Cholangitis, Pruritus, regulatory, SmithKline Beecham

GSK, Linerixibat, PBC Itch, Phase 3 Trial, Regulatory Filings, Cholestatic Pruritus

NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo

1 year ago talkbio0Tagged AstraZeneca, Daiichi, England, Enhertu, Malignant neoplasm of breast, Nance-Horan syndrome, NHS, Nitroglycerin/Sodium Citrate/Ethanol Solution, Sankyo

Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

1 year ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Regenxbio Advances Duchenne Muscular Dystrophy Gene Therapy to Pivotal Studies, Potentially Challenging Sarepta’s Dominance

1 year ago talkbio0Tagged Approved, Biologics License Application, DMD, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regenxbio, SLC6A8 Inhibitor RGX-202, United States Food and Drug Administration

Regenxbio, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), Gene Therapy, RGX-202, Elevidys, Pivotal Studies, Biologics License Application (BLA), FDA Approval

Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments

1 year ago talkbio0Tagged Breakthrough Therapy, Clinical Trials, Cybin, Hallucinogens, Identifier, mental health, N,N-Dimethyltryptamine, Psilocybin, United States Food and Drug Administration

Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.